The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review

JAAD International Pub Date : 2024-08-16 DOI:10.1016/j.jdin.2024.06.006

Marie Vangilbergen MD , Aline Stockman MD , Axelle Van De Velde MD , Maria Garmyn MD, PhD , Kevin Punie MD, PhD , Tom Hillary MD, PhD

{"title":"The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review","authors":"Marie Vangilbergen MD , Aline Stockman MD , Axelle Van De Velde MD , Maria Garmyn MD, PhD , Kevin Punie MD, PhD , Tom Hillary MD, PhD","doi":"10.1016/j.jdin.2024.06.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Biologicals targeting interleukin (IL)-17 and IL-23 improve quality of life in psoriasis and other chronic autoimmune disorders with a favorable safety profile. However, current guidelines do not recommend their use in patients with recent oncologic history due to limited evidence.</div></div><div><h3>Objective</h3><div>To understand the impact of IL-17 and IL-23 inhibitors on cancer development, progression, and recurrence by systematically reviewing available literature.</div></div><div><h3>Methods</h3><div>We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.</div></div><div><h3>Results</h3><div>Most studies investigating the use of IL-23 and IL-17 blockers did not find a higher incidence of cancer compared to the general population. One study observed no relapse in patients with a history of cancer.</div></div><div><h3>Limitations</h3><div>The systematic review is limited due to variations in study designs and outcomes, making it difficult to achieve a comprehensive synthesis and comparison between studies. Furthermore, small sample sizes were notable.</div></div><div><h3>Conclusion</h3><div>Preclinical studies suggest that treating psoriasis with IL-17 or IL-23 blockers is safe, also in patients witch active cancer or a history of it. Pharmacovigilance data show no increased malignancy rate in patients treated with these treatment modalities. However, data on relapse in patients with a history or active malignancy are limited.</div></div>","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"17 ","pages":"Pages 71-79"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAAD International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266632872400110X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Biologicals targeting interleukin (IL)-17 and IL-23 improve quality of life in psoriasis and other chronic autoimmune disorders with a favorable safety profile. However, current guidelines do not recommend their use in patients with recent oncologic history due to limited evidence.

Objective

To understand the impact of IL-17 and IL-23 inhibitors on cancer development, progression, and recurrence by systematically reviewing available literature.

Methods

We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Results

Most studies investigating the use of IL-23 and IL-17 blockers did not find a higher incidence of cancer compared to the general population. One study observed no relapse in patients with a history of cancer.

Limitations

The systematic review is limited due to variations in study designs and outcomes, making it difficult to achieve a comprehensive synthesis and comparison between studies. Furthermore, small sample sizes were notable.

Conclusion

Preclinical studies suggest that treating psoriasis with IL-17 or IL-23 blockers is safe, also in patients witch active cancer or a history of it. Pharmacovigilance data show no increased malignancy rate in patients treated with these treatment modalities. However, data on relapse in patients with a history or active malignancy are limited.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

白细胞介素-17 和白细胞介素-23 抑制剂在癌症发生、发展和复发中的作用：系统综述

背景针对白细胞介素（IL）-17和IL-23的生物制剂可改善银屑病和其他慢性自身免疫性疾病患者的生活质量，且安全性良好。方法我们根据《系统综述和荟萃分析首选报告项目》指南进行了一项系统综述。结果大多数调查IL-23和IL-17阻断剂使用情况的研究并未发现与普通人群相比癌症发病率更高。局限性由于研究设计和结果存在差异，系统性综述受到了限制，因此很难对各项研究进行全面综合和比较。结论临床前研究表明，使用IL-17或IL-23阻断剂治疗银屑病是安全的，对于患有活动性癌症或有癌症史的患者也是安全的。药物警戒数据显示，使用这些治疗方法的患者恶性肿瘤发生率没有增加。不过，关于有恶性肿瘤病史或活动性恶性肿瘤患者复发的数据还很有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊